Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021

Summary

The publisher’s "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

CD-19 and CD-20 inhibitors are a major focus of drug developers. There are 387 drugs in the pipeline, 95x% 0f which are in early-stage. Big Pharma companies dominates R&D in this indication with Roche leading the way. The addition of several high-priced therapies is expected to drive market growth, but cost savings due to biosimilar drugs will act as a strong barrier to market growth.

This reports provides a data-driven overview of the current and future competitive landscape in DLBCL therapeutics.

Scope

Components of the report include -

• Disease epidemiology
• Marketed drugs assessment
• Pipeline drugs assessment
• Clinical trials assessment
• Commercial assessment
• Social media overview
• Digital marketing overview

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global DLBCL market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DLBCL in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.